Pharma BD Deal Intelligence
Lilly acquires biotechnology company Prevail Therapeutics for $1.04 billion to advance gene therapy capabilities in neuroscience
Lilly discontinued LY3884963 (FTD-GRN gene therapy from Prevail) due to lack of compelling efficacy; not a safety concern. One of three programs stopped.
PR001/LY3884961 Phase 1/2a PROPEL in GBA1-Parkinson's: ACTIVE_NOT_RECRUITING, primary completion estimated December 2030.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Lilly acquired Prevail Therapeutics for $1.0B upfront ($22.50/share in cash, ~$1.04B enterprise value) plus a non-tradeable CVR worth up to $4.00/share, closing January 22, 2021, to establish a neuroscience gene-therapy platform. The lead asset, PR001/LY3884961, is an AAV9 gene therapy for GBA1-mutation Parkinson's disease and neuronopathic Gaucher disease, evaluated in the Phase 1/2a PROPEL trial (NCT04127578) — still active (not recruiting) with primary completion now estimated December 2030. The thesis was a portfolio of clinical and preclinical neurodegeneration gene therapies, but it has narrowed: in February 2026 Lilly discontinued the PR006/LY3884963 program for frontotemporal dementia with progranulin mutations (PROCLAIM trial, NCT04408625) citing lack of compelling efficacy (no safety concern), as part of a broader cut of three pipeline programs. The deal remains a long-dated, early-/mid-stage neuro bet: the lead Parkinson's program is alive but pre-revenue with a 2030 readout, while one of the two named clinical assets has now failed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Prevail Therapeutics (this deal) | 2020 | $1.0B | 48 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2020 deals · Eli Lilly and Company deals · Metabolic deals